17,261 trials
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Dystonia
Primary: Physician Global Perception of Change - Blinded Rater 1 — 1; 1; 1; 4 Participants
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Diabetic Macular Edema
Primary: Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — 22; 22; 22; 22 Participants
Hypercholesterolemia · Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180 — 9.0; -47.6; -51.9; -56.3 percent change in LDL-C — p=<.0001
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Inclusion Body Myositis
Primary: Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score — -3.26; -2.26 score on a scale — p=0.1146
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Number of Participants With PSA Remission Assessed Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria — 29; 16 Participants
Alcohol Use Disorder
Primary: Alcohol Quantity — 27.37; 25.95; 32.02; 32.15 number of drinks on peak occasion — p=.461
Onchocerciasis
Primary: Rates of Severe Adverse Events (SAEs) Across Study Arms — 0; 0; 0 Participants
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
Uterine Cervical Neoplasms
Primary: Number of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent…
Chronic Hand Dermatitis
Primary: Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) — -49.5; -71.3; -29.9 percentage change
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
Alzheimer's Disease
Primary: Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations — 0; 0; 0; 0 events